Revelation Biosciences Submits End-of-Phase 1 Meeting Package to FDA, On Track for Meeting Later This Year

Revelation Biosciences is on track to hold an end-of-phase 1 meeting with the FDA later this year to discuss Gemini's treatment for acute kidney injury (AKI). The company recently announced positive safety and activity data from its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease patients. Revelation plans to publish additional results from the study and expand Gemini's potential uses through preclinical and clinical testing.